Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD)

Clinical and Experimental Immunology

Volumn 109, Issue 3, 1997, Pages 533-537

  Bengtsson, A ^c   Holm, L ^a   Back O ^b   Fransson, J ^c   Scheynius, A ^c  

^a Sophiahemmet Hospital   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atopic dermatitis; IgE psoriasis; Seborrhoeic dermatitis; Soluble CD30

Indexed keywords

CD30 ANTIGEN; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN E; KETOCONAZOLE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; PSORIASIS; SEBORRHEIC DERMATITIS; T LYMPHOCYTE ACTIVATION;

EID: 0030762210     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4731373.x     Document Type: Article

References (32)

1. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299:65-67.
2. Burns BF, Dardick I. Ki-1-positive non-Hodgkin's lymphomas. An immunophenotypic, ullrastructural, and morphometric study. Am J Clin Pathol 1990; 93:327-32.
3. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66:848-58.
4. + T cells. J Immunol 1993; 151:2380-9.
5. Dürkop H, Latza U, Hummel M et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68:421-7.
6. Alzona M, Jäck H-M, Fisher RI et al. CD30 defines a subset of activated human T cells that produce IFN-γ and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994; 153:2861-7.
7. + T cells producing Th-2 type cytokines. FASEB J 1995; 9:81-86.
8. Bengtsson Å, Johansson C, Tengvall Linder M et al. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J Leuk Biol 1995; 58:683-9.
9. Hamann D, Hilkens CMU, Grogan JL et al. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996; 156:1387-91.
10. Josimovic-Alasevic O, Dürkop D, Schwarting R et al. Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19:157-62.
11. Hansen HP, Kisseleva T, Koharg J et al. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995; 63:750-6.
12. Pizzolo G, Vinante F, Morosato L et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994; 8:741-5.
13. Fattovich G, Vinante F, Giustina G et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103:105-10.
14. Chilosi M, Facchetti F, Notarangelo LD et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol 1996; 26:329-34.
15. Caligaris-Cappio F, Bertero MT, Converso M et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13:339-43.
16. Nadali G, Vinante F, Ambrosetti A et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12:793-7.
17. Öhman S, Johansson SGO. Immunoglobulins in atopic dermatitis. Acta Derm Venerol (Stockh) 1974; 54:193-202.
18. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994; 102:128-37.
19. Romagnani S. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Immunol 1992; 98:279-85.
20. van Reijsen FC, Bruijnzeel-Koomen CAFM, Kalthoff FS et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90:184-92.
21. Tengvall Linder M, Johansson C, Zargari A et al. Detection of Pityrosporum orbiculare reactive T cells from skin and blood in atopic dermatitis and characterization of their cytokine profiles. Clin Exp Allergy 1996; 26:1286-97.
22. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) Suppl. 1980; 92:44-47.
23. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: The SCORAD index. Dermatology 1993; 186:23-31.
24. Back O, Scheynius A, Johansson SGO. Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE, Arch Dermatol Res 1995; 287:448-51.
25. Esnault S, Benbernou N, Lavaud F et al. Spontaneous CD30 mRNA expression in peripheral blood mononuclear cells from atopic patients with high IgE serum levels. Clin Exp Immunol 1996; 106:67-72.
26. Pfreundschuh M, Pohl C, Berenbeck C et al. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer 1990; 45:869-74.
27. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101:701-5.
28. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgaris belong to the ThI subset. J Invest Dermatol 1994; 102:145-9.
29. Neuber K, Kröger S, Gruseck E et al. Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN-γ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996; 288:532-6.
30. Smith CA, Gruss H-J, Davis T et al. CD30 antigen, a marker for Hodgkin's lymphoma is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73:1349-60.
31. Gruss H-J, Boiani N, Williams DE et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83:2045-56.
32. Amakawa R. Hakem A, Kundig TM et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84:551-62.